The Cure Sickle Cell Initiative: Catalyzing Progress via Innovative Interfaces Between NIH, Patients, Academics, ASH, and the Private Sector
Dr. Edward Benz provides some background on the discovery of sickle cell disease and development of the Cure Sickle Cell Initiative. Dr. Ify Osunkwo adds further perspectiv
A New Standard of Care for Children and Young Adults With T-cell Acute Lymphoblastic Leukemia
Dr. Teachey reviews a study that shows outstanding outcomes for children and young adults with T-cell acute lymphoblastic leukemia that have raised the bar and established
Dr. Michaelis covers some of her goals and ideas as the new Editor-in-Chief of The Hematologist and discusses the importance of using this medium to share data, important information, and stories of patients we meet along the way, to move forward the field of hematology.
Dr. Keel looks at a study that reviews the use of eltrombopag in combination with antithymocyte globulin and cyclosporine in refractory severe aplastic anemia treatment-naive patients, among other studies.
Dr. Linkins considers oral direct anticoagulants as an attractive alternative to low-molecular-weight heparin injections to treat patients with cancer-associated VTE.
Dr. Moll discusses the ATTRACT Trial, which demonstrated that catheter-directed pharmacomechanical thrombolysis did not prevent the development of PTS in patients with acute proximal DVT, but increased the risk for major bleeding.
Dr. Raje and Dr. Yee look at the RVD regimen (lenalidomide, bortezomib, and dexamethasone) as standard of care in newly diagnosed multiple myeloma.
Dr. Moss covers several trials that have solidified the use of venetoclax as the new backbone within a range of combination therapies that should achieve extremely deep therapeutic responses in CLL.
Dr. Abdel-Wahab reviews the FDA approval in 2017 of four new therapeutic options for treating acute myeloid leukemia patients.
Drs. George and Conant review a study that shows that in patients with unexplained cytopenias, the detection of somatic mutations can stratify patients into being at low or high risk for developing myeloid malignancies. CHIP has clinical impact beyond increased risk for developing hematopoietic neoplasms and may have further implications in nonhematologic areas.
Dr. Jacobson looks at two randomized trials that demonstrate a benefit of antibody therapy against CD20 in new contexts in mantle cell lymphoma and follicular lymphoma 20 years after the initial FDA approval of rituximab to treat B cell lymphoma.
Dr. Hoggatt covers successes in gene therapy achieved during 2017 and expresses excitement in what's to come for the field.
November-December 2018Volume 15, Issue 6
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology